{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T08:25:37Z","timestamp":1791015937840,"version":"4.1.0"},"reference-count":46,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.15656","type":"journal-article","created":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T14:08:53Z","timestamp":1599055733000},"page":"e2015656","source":"Crossref","is-referenced-by-count":58,"title":["Association of Sociodemographic Factors With Immunotherapy Receipt for Metastatic Melanoma in the US"],"prefix":"10.1001","volume":"3","author":[{"given":"Justin T.","family":"Moyers","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Loma Linda University, Loma Linda, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amie","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Loma Linda University, Loma Linda, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Shih","sequence":"additional","affiliation":[{"name":"School of Public Heath, Loma Linda University, Loma Linda, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayathri","family":"Nagaraj","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Loma Linda University, Loma Linda, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2020,9,2]]},"reference":[{"issue":"36","key":"zoi200582r1","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification.","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi200582r2","first-page":"488","article-title":"Treatment of metastatic melanoma: an overview.","volume":"23","author":"Bhatia","year":"2009","journal-title":"Oncology (Williston Park)"},{"issue":"7","key":"zoi200582r3","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.","volume":"17","author":"Atkins","year":"1999","journal-title":"J Clin Oncol"},{"key":"zoi200582r4","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.00198","article-title":"Systemic therapy for melanoma: ASCO guideline.","author":"Seth","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi200582r5","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma.","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi200582r7","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"issue":"26","key":"zoi200582r8","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma.","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi200582r10","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation.","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi200582r12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"zoi200582r13","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma.","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"zoi200582r14","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma.","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi200582r16","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jaad.2019.05.079","article-title":"Factors associated with time to surgery in melanoma: an analysis of the National Cancer Database.","volume":"81","author":"Baranowski","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"zoi200582r17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1159\/000468152","article-title":"Disparities in the presentation and management of cutaneous melanoma that required admission.","volume":"95","author":"Al-Qurayshi","year":"2018","journal-title":"Oncology"},{"issue":"1","key":"zoi200582r18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/CJI.0000000000000294","article-title":"Association of insurance status with presentation, treatment, and survival in melanoma in the era of immune checkpoint inhibitors.","volume":"43","author":"Jain","year":"2020","journal-title":"J Immunother"},{"issue":"1","key":"zoi200582r19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1017\/S0714980810000796","article-title":"Socioeconomic status and chemotherapy use for melanoma in older people.","volume":"30","author":"Reyes-Ortiz","year":"2011","journal-title":"Can J Aging"},{"issue":"35","key":"zoi200582r20","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1200\/JCO.2017.73.7817","article-title":"Changes in insurance coverage and stage at diagnosis among nonelderly patients with cancer after the Affordable Care Act.","volume":"35","author":"Jemal","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi200582r22","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1377\/hlthaff.2016.1632","article-title":"Medicaid expansion and state trends in Supplemental Security Income program participation.","volume":"36","author":"Soni","year":"2017","journal-title":"Health Aff (Millwood)"},{"issue":"4","key":"zoi200582r23","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1377\/hlthaff.2017.1390","article-title":"Effects of the ACA\u2019s health insurance marketplaces on the previously uninsured: a quasi-experimental analysis.","volume":"37","author":"Goldman","year":"2018","journal-title":"Health Aff (Millwood)"},{"issue":"6","key":"zoi200582r28","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1245\/s10434-019-07213-1","article-title":"Incident cases captured in the National Cancer Database compared with those in U.s. population based central cancer registries in 2012-2014.","volume":"26","author":"Mallin","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"zoi200582r29","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1111\/ijd.2018.57.issue-10","article-title":"Socioeconomic status and survival for patients with melanoma in the United States: an NCDB analysis.","volume":"57","author":"Sitenga","year":"2018","journal-title":"Int J Dermatol"},{"issue":"6","key":"zoi200582r30","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/CJI.0000000000000264","article-title":"Racial and socioeconomic disparities in the delivery of immunotherapy for metastatic melanoma in the United States.","volume":"42","author":"Haque","year":"2019","journal-title":"J Immunother"},{"issue":"15","key":"zoi200582r31","doi-asserted-by":"publisher","first-page":"9525","DOI":"10.1200\/JCO.2019.37.15_suppl.9525","article-title":"Immunotherapy disparities in metastatic melanoma.","volume":"37","author":"Oliver","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"zoi200582r32","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s00262-018-2241-x","article-title":"Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies.","volume":"67","author":"Dobry","year":"2018","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"zoi200582r33","first-page":"2897","article-title":"Disparities of immunotherapy utilization in patients with stage III cutaneous melanoma: a national perspective.","volume":"38","author":"Al-Qurayshi","year":"2018","journal-title":"Anticancer Res"},{"issue":"12","key":"zoi200582r34","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1001\/jamaoncol.2018.3467","article-title":"Comparison of insurance status and diagnosis stage among patients with newly diagnosed cancer before vs after implementation of the Patient Protection and Affordable Care Act.","volume":"4","author":"Han","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"zoi200582r35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ijrobp.2017.12.006","article-title":"Health care disparities in cancer patients receiving radiation: changes in insurance status after Medicaid expansion under the Affordable Care Act.","volume":"101","author":"Chino","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"zoi200582r36","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.21653","article-title":"Association of Medicaid expansion under the Affordable Care Act with insurance status, cancer stage, and timely treatment among patients with breast, colon, and lung cancer.","volume":"3","author":"Takvorian","year":"2020","journal-title":"JAMA Netw Open"},{"key":"zoi200582r37","doi-asserted-by":"crossref","DOI":"10.1097\/DSS.0000000000002316","article-title":"Mohs surgery for SEER registry-captured melanoma in situ and rare cutaneous tumors: comparing national utilization patterns before and after implementation of the Affordable Care Act (2010) and appropriate use criteria (2012).","author":"Garland","year":"2020","journal-title":"Dermatol Surg"},{"issue":"1","key":"zoi200582r38","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.19697","article-title":"Association of type of treatment facility with overall survival after a diagnosis of head and neck cancer.","volume":"3","author":"Carey","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"7","key":"zoi200582r39","doi-asserted-by":"publisher","first-page":"837","DOI":"10.6004\/jnccn.2016.0088","article-title":"Value, access, and cost of cancer care delivery at academic cancer centers.","volume":"14","author":"Nardi","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"zoi200582r40","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju002","article-title":"Comparison of survival outcomes among cancer patients treated in and out of clinical trials.","volume":"106","author":"Unger","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"zoi200582r41","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.jval.2017.04.003","article-title":"Predicting real-world effectiveness of cancer therapies using overall survival and progression-free survival from clinical trials: empirical evidence for the ASCO value framework.","volume":"20","author":"Lakdawalla","year":"2017","journal-title":"Value Health"},{"issue":"2","key":"zoi200582r42","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1001\/jamaoncol.2018.4514","article-title":"Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial.","volume":"5","author":"Ascierto","year":"2019","journal-title":"JAMA Oncol"},{"issue":"28","key":"zoi200582r43","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000016328","article-title":"Real-world treatment patterns and clinical outcomes among patients with advanced melanoma: a retrospective, community oncology-based cohort study (a STROBE-compliant article).","volume":"98","author":"Cowey","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"zoi200582r44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/CCI.18.00155","article-title":"An exploratory analysis of real-world end points for assessing outcomes among immunotherapy-treated patients with advanced non-small-cell lung cancer.","volume":"3","author":"Stewart","year":"2019","journal-title":"JCO Clin Cancer Inform"},{"key":"zoi200582r45","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ejca.2018.01.062","article-title":"Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma.","volume":"93","author":"T\u00e9tu","year":"2018","journal-title":"Eur J Cancer"},{"issue":"12","key":"zoi200582r46","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1001\/jamaoncol.2016.6905","article-title":"Using the National Cancer Database for outcomes research: a review.","volume":"3","author":"Boffa","year":"2017","journal-title":"JAMA Oncol"},{"key":"zoi200582r25","first-page":"1","volume-title":"Health Insurance Coverage And The Affordable Care Act, 2010\u20132016. ASPE Issue Brief","author":"Uberoi","year":"2016"},{"key":"zoi200582r26","first-page":"9","volume-title":"Changes in Health Insurance Coverage 2013\u20132016: Medicaid Expansion States Lead the Way","author":"Skopec","year":"2018"},{"key":"zoi200582r27","volume-title":"What All Data Users Need to Know","author":"Understanding and Using American Community Survey Data","year":"2018"},{"key":"zoi200582r6","unstructured":"US Food and Drug Administration. Ipilimumab BLA approval letter; 125514\/0. March 25, 2011. Accessed February 8, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2011\/125377s000ltr.pdf"},{"key":"zoi200582r9","unstructured":"US Food and Drug Administration. Pembrolizumab BLA approval Letter; BL 125377\/0. Accessed February 8, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2014\/125514Orig1s000ltr.pdf"},{"key":"zoi200582r11","unstructured":"US Food and Drug Administration. Nivolumab accelerated approval letter; 125554\/S-002. Accessed February 8, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2014\/125554Orig1s000ltr.pdf"},{"key":"zoi200582r15","unstructured":"US Food and Drug Administration. Nivolumab sBLA accelerated approval letter; 125554\/007. Accessed February 10, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2016\/125554Orig1s007ltr.pdf"},{"key":"zoi200582r21","unstructured":"Institute of Medicine. Key Features of the Affordable Care Act by Year. National Academies Press; 2014. Accessed February 8, 2020. https:\/\/www.hhs.gov\/healthcare\/facts\/timeline\/timeline-text.html"},{"key":"zoi200582r24","unstructured":"US Food and Drug Administration. Talimogene laherparepvec BLA approval letter; 125518\/0. Accessed February 10, 2020. https:\/\/www.fdanews.com\/ext\/resources\/files\/04-15\/Amgen-T-vec-briefing-document.pdf?1520905727"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2770145\/moyers_2020_oi_200582_1602708686.28227.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T17:01:22Z","timestamp":1602694882000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2770145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,2]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.15656","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,2]]}}}